Varex Imaging (VREX) Q2 2026 earnings review
Top-Line Stagnates While Margins and Cash Flow Retreat
Varex Imaging delivered a highly subdued Q2 FY26, with revenue eking out just 1% YoY growth to $216 million. While management points to 'solid demand' and a favorable 2H setup, the bottom line paints a Decelerating picture. Non-GAAP gross margins compressed by 240 basis points to 33.9%, driving a sharp 32% collapse in Non-GAAP EPS ($0.21 vs $0.31 last year). The aggressive inventory buildup designed to support future shipments triggered a Reversing trend in operating cash flow, flipping to a $2 million outflow. Guidance for Q3 implies an acceleration in revenue (+7% YoY at the midpoint), but profitability will require stringent execution to rebound.
🐂 Bull Case
Management expects 2H FY26 revenue to be up approximately 3% compared to 2H FY25, relying on favorable demand dynamics in global CT and cargo systems. Q3 revenue guidance of $210M-$225M implies a healthy acceleration.
The company successfully executed its debt redemption and refinancing in March. This simplifies the balance sheet, retiring near-term convertible note maturities.
🐻 Bear Case
Non-GAAP operating margin Decelerating from 12.2% to 8.9% YoY is a massive hit. Varex must prove it can manage its cost of goods sold and tariff impacts without sacrificing profitability.
Cash and marketable securities plunged from $155 million at FY25 end to $88 million, driven not only by debt reduction but also by a $2 million operating cash outflow tied to swelling inventory.
⚖️ Verdict: 🔴
Bearish. While revenue met baseline expectations, the aggressive margin contraction, cash burn, and the sudden slowdown of the previously high-flying Industrial segment raise execution concerns.
Key Themes
Industrial Segment Momentum Evaporates
Management touted 'continued momentum' across the Industrial business, but the numbers tell a contradictory story. Industrial revenue grew a paltry 1.2% YoY in Q2 FY26 to $59.8 million. This is severely Decelerating compared to the 17% growth in Q1 FY26 and the 25% surge in Q4 FY25. The lumpiness of the tender-driven cargo security business is showing its downside.
Operating Profitability Squeezed
Despite flat revenue YoY, profitability metrics declined significantly. Non-GAAP Gross Margin fell from 36.3% to 33.9%, and Non-GAAP Operating Margin contracted from 12.2% to 8.9%. Rising OpEx ($53.9M non-GAAP vs $51.4M YoY) coupled with lower gross margins highlights negative operating leverage.
Reversing Cash Flow and Swelling Inventory
Operating Cash Flow turned negative, printing a $2 million outflow compared to a strong $17 million inflow in the same quarter last year. Management cited 'increased working capital associated with inventory to support anticipated demand and future shipments.' Given the Decelerating revenue growth, tying up more cash in inventory increases risk if the promised 2H volume rebound falters.
Macro: Tariffs Remain a Blind Spot
Geopolitics continue to act as a headwind. Management explicitly noted that guidance assumes zero benefit from International Emergency Economic Powers Act (IEEPA) tariff refunds, despite having applied for them. Without pricing power or supply chain realignment fully offsetting these costs, tariffs will continue anchoring gross margins.
Global CT Volume Anchoring the Medical Base
Medical segment revenue was Stable, coming in at $156 million (+1.5% YoY). Management explicitly called out 'global CT' as a driver of solid demand. Given the severe fluctuations previously seen in the China high-end CT market, stabilizing Medical volumes provide a floor for overall company revenue.
Cargo Systems Resiliency
While growth slowed sequentially, management maintains that cargo systems remain a fundamental driver for the business setup in 2H FY26. Varex's shift to a fully integrated subsystem provider allows it to compete on tender offers that stretch across the next 12-18 months.
Photon Counting Detectors
Technology adoption is highlighted as a specific growth vector. Photon counting detectors enable superior image resolution and reduced radiation doses. Management named this technology directly alongside CT and cargo as one of the three main pillars driving current momentum across both Medical and Industrial.
Other KPIs
A sharp drop from $155 million at the end of FY25. The decline primarily reflects the execution of debt redemption and refinancing in March, which de-risks the maturity wall but leaves Varex with a thinner cash cushion amidst negative operating cash flows.
Reversing to a loss from a $7.1 million GAAP profit in 25Q2. The GAAP results were heavily impacted by $9.4 million in 'other non-operational costs' related to the early extinguishment, modification, and refinancing of debt.
Guidance
Accelerating. The midpoint of $217.5M implies a 7.1% YoY growth rate compared to $203M in 25Q3, marking a sequential step-up in growth momentum vs the 1% seen this quarter.
Accelerating YoY. The $0.225 midpoint implies robust growth against the weak $0.13 adjusted non-GAAP EPS posted in 25Q3, yet it sits below the $0.26 originally reported before Varex adjusted its non-GAAP equity accounting methodology.
Stable. The $870 million midpoint implies ~3% YoY growth compared to the $844.6 million booked in FY25. With $425.6M banked in H1, the company needs $444.4M in H2 to hit the midpoint, aligning with their statement that 2H revenue will be up ~3% vs last year.
Stable. The $0.90 midpoint is exactly flat compared to the restated $0.94 achieved in FY25. This underscores the core issue: revenue volume growth is being entirely neutralized by margin compression and increased interest/operating expenses.
Key Questions
Industrial Segment Deceleration
Industrial revenue growth fell from 17% in Q1 to just 1% in Q2. Was this purely a timing issue with large cargo system tender deliveries, or is there a structural slowdown in order intake?
Inventory Conversion Timeline
With operating cash flow turning negative to support an inventory build, when precisely do you expect these higher raw material and WIP levels to convert into finished goods shipments and free cash flow?
Tariff Mitigation Efficacy
Given non-GAAP gross margins fell 240 bps to 33.9%, to what extent are higher supply chain costs and tariffs offsetting your historical productivity gains, and when do your local-for-local manufacturing initiatives structurally repair this margin?